These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 17136449)

  • 1. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
    Vermeulen A; Piotrovsky V; Ludwig EA
    J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.
    Sherwin CM; Saldaña SN; Bies RR; Aman MG; Vinks AA
    Ther Drug Monit; 2012 Oct; 34(5):535-44. PubMed ID: 22929407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
    Vandenberghe F; Guidi M; Choong E; von Gunten A; Conus P; Csajka C; Eap CB
    Clin Pharmacokinet; 2015 Dec; 54(12):1259-72. PubMed ID: 26129906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.
    Cho HY; Lee YB
    Arch Pharm Res; 2006 Jun; 29(6):525-33. PubMed ID: 16833023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.
    Yoo HD; Cho HY; Lee SN; Yoon H; Lee YB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):329-41. PubMed ID: 22623266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
    Calarge CA; Miller del D
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):163-9. PubMed ID: 21486167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
    Kneller LA; Hempel G
    Pharm Res; 2020 May; 37(6):110. PubMed ID: 32476097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
    Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
    J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
    Gunes A; Spina E; Dahl ML; Scordo MG
    Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].
    Ding JJ; Jiao Z; Yu YQ; Shi XJ
    Yao Xue Xue Bao; 2007 Jun; 42(6):631-8. PubMed ID: 17702401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
    Kneller LA; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions.
    LLerena A; Berecz R; Dorado P; de la Garza CS; Norberto MJ; Cáceres M; Gutiérrez JR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):213-9. PubMed ID: 12450541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers.
    Lee DY; Lee KU; Kwon JS; Jang IJ; Cho MJ; Shin SG; Woo JI
    Psychopharmacology (Berl); 1999 Jun; 144(3):272-8. PubMed ID: 10435394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
    Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
    J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
    Molden E; Waade RB; Hoff M; Haslemo T
    Basic Clin Pharmacol Toxicol; 2016 Nov; 119(5):470-475. PubMed ID: 27145399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
    Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
    J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia.
    Nagasaki T; Ohkubo T; Sugawara K; Yasui N; Furukori H; Kaneko S
    J Pharm Biomed Anal; 1999 Mar; 19(3-4):595-601. PubMed ID: 10704125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of venlafaxine on the pharmacokinetics of risperidone.
    Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
    J Clin Pharmacol; 1999 Mar; 39(3):297-309. PubMed ID: 10073330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.